Convalescent Plasma Infusion to Decrease Coronavirus Associated Complications: An Open label, observational study of feasibility and safety of COVID-19 Convalescent plasma in hospitalized patients with severe and life-threatening COVID-19

Overview

The purpose of this study is to see if convalescent plasma will help treat COVID-19.

Description

Participants will receive plasma from a person who has recovered from COVID-19. Researchers will collect information from participants' medical record as well as blood samples on days 1, 3, 7, 14, and 28.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    COVID-19
  • Age: Between 12 Years - 100 Years
  • Gender: All

Individuals at least 12 years of age hospitalized with severe or critical COVID-19 respiratory symptoms.

Individuals with contraindication to transfusion or history of prior reactions to transfusion blood products.

Updated on 20 Nov 2022. Study ID: 2004139923

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center